Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment -na?ve or Pre-treated Advanced D

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc